DNDi aims to deliver:

  • A solid first-line “4-in-1” fixed-dose combination of abacavir/lamivudine/lopinavir/ritonavir for infants and young children under three years of age
  • Immediate introduction of the US FDA approved “2-in-1” LPV/r pellets, to replace high-alcohol syrups, before the availability of better-adapted 4-in-1 products.

 

The current paediatric HIV portfolio includes:

Development

Development

‘4-in-1’ ABC/3TC/LPV/r
LPV/r pellets with dual NRTI FDC

Implementation

Implementation

Superbooster therapy paediatric HIV/TB

 

For more details on each project, see DNDi‘s Global Portfolio